Barinthus Biotherapeutics (BRNS) Income from Non-Controlling Interests (2020 - 2026)
Barinthus Biotherapeutics' (BRNS) quarterly Income from Non-Controlling Interests came in at -$3000.0 in Q1 2026, up 57.14% YoY from -$1909.1 in Q1 2025, and up 40.0% on a QoQ basis from -$5000.0 in Q4 2025.
Barinthus Biotherapeutics (BRNS) Income from Non-Controlling Interests (2020 - 2026) Analysis & Trends
Barinthus Biotherapeutics (BRNS) has 7 years of Income from Non-Controlling Interests data on file, last reported at -$3000.0 in Q1 2026.
- Quarterly Income from Non-Controlling Interests rose 57.14% year-over-year to -$3000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$8000.0 (up 91.92% YoY) and the FY2025 annual result came in at -$22000.0, up 79.82% from the prior year.
- Income from Non-Controlling Interests rose to -$3000.0 in Q1 2026, from -$5000.0 in the prior quarter.
- In the past five years, Income from Non-Controlling Interests ranged from a high of $26000.0 in Q4 2022 to a low of -$65000.0 in Q4 2024.
- A 5-year average of -$15647.1 and a median of -$12000.0 in 2024 frame the typical range for Income from Non-Controlling Interests.
- Annual changes were most pronounced in 2022 — Income from Non-Controlling Interests jumped 144.83% — and 2024, when it plunged 1183.33%.
- Tracing BRNS's Income from Non-Controlling Interests over 5 years: stood at $26000.0 in 2022, then slumped by 76.92% to $6000.0 in 2023, then sank by 1183.33% to -$65000.0 in 2024, then soared by 92.31% to -$5000.0 in 2025, then jumped by 40.0% to -$3000.0 in 2026.
- The last three Income from Non-Controlling Interests figures came in at -$3000.0 (Q1 2026), -$5000.0 (Q4 2025), and -$5000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 63.60 Mn |
| 10 | Barinthus Biotherapeutics | 25.40 Mn | 25.40 Mn | - | -19,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -19,000.00 |
| Mar 31, 2026 | -3,000.00 |
| Dec 31, 2025 | -5,000.00 |
| Sep 30, 2025 | -5,000.00 |
| Jun 30, 2025 | 5,000.00 |
| Mar 31, 2025 | -7,000.00 |
| Dec 31, 2024 | -65,000.00 |
| Sep 30, 2024 | -15,000.00 |
| Jun 30, 2024 | -12,000.00 |
| Mar 31, 2024 | -31,000.00 |
| Dec 31, 2023 | 6,000.00 |
| Sep 30, 2023 | -48,000.00 |
| Jun 30, 2023 | -22,000.00 |
| Mar 31, 2023 | -43,000.00 |
| Dec 31, 2022 | 26,000.00 |
| Sep 30, 2022 | -21,000.00 |
| Jun 30, 2022 | -4,000.00 |
| Mar 31, 2022 | -22,000.00 |
| Dec 31, 2021 | -58,000.00 |
| Sep 30, 2021 | -13,000.00 |